| Title | Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma. |
| Publication Type | Journal Article |
| Year of Publication | 2019 |
| Authors | Hernandez A, Brandler TC, Zhou F, Moreira AL, Schatz-Siemers N, Simsir A |
| Journal | Am J Clin Pathol |
| Volume | 151 |
| Issue | 4 |
| Pagination | 403-415 |
| Date Published | 2019 03 01 |
| ISSN | 1943-7722 |
| Keywords | Adenocarcinoma of Lung, Aged, Aged, 80 and over, B7-H1 Antigen, Biopsy, Fine-Needle, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged |
| Abstract | OBJECTIVES: To evaluate whether non-small cell lung carcinoma (NSCLC) cytology specimens are reliable for programmed death-ligand 1 (PD-L1) immunohistochemical (IHC) testing. METHODS: Fifty-two cell blocks (CBs) with corresponding surgical pathology PD-L1 IHC testing were stained with a Dako PD-L1 pharmDX antibody (clone-22C3). Tumor cellularity was recorded as <100 or ≥100 cells. PD-L1 IHC was scored by percentage of tumor cells staining (<1%, ≥1%-49%, ≥50%) and compared between matched cases. RESULTS: Substantial agreement (κ = 0.63; 95% CI, 0.53-0.73) was reached between matched CB and surgical cases in CBs with ≥100 tumor cells compared to CBs with <100 tumor cells (slight agreement, κ = 0.19; 95% CI, 0.04-0.35). Overall, there was 67% agreement among paired cases (35/52 cases, κ = 0.51; 95% CI, 0.42-0.60). CONCLUSIONS: CBs can be utilized for PD-L1 IHC testing, as illustrated by the 67% agreement between CB and surgical cases in our study. Disagreement is attributable to intratumoral heterogeneity and CB cellularity. |
| DOI | 10.1093/ajcp/aqy164 |
| Alternate Journal | Am J Clin Pathol |
| PubMed ID | 30534975 |
Related Faculty:
Nina Schatz-Siemers, D.O.